NYBC Ventures
Corporate VCNew York · Seed–Series B · 8 people tracked
Investment thesis
NYBC Ventures is a corporate venture fund launched by New York Blood Center Enterprises with a $50M commitment to accelerate breakthroughs in blood and cellular therapies and supporting technologies. It leverages New York Blood Center's decades of expertise in blood products, transfusion services, and cell and gene therapy manufacturing. The fund targets early to mid stage innovations across hematology, transfusion medicine, cell therapy, and infectious disease, supporting therapeutics, devices, and other breakthrough solutions that address key challenges in these fields and ultimately improve patient lives.
Source: firm website, verified Aug 7, 2026.
Team · 8 people
from the firm's website & public directoriesWhat they invest in
from 13 of 15 portfolio companiesBiotech ×11Healthtech ×9Medical Devices ×8Deep Tech ×5Advanced Manufacturing ×2Digital Health ×2Robotics ×2AI & Machine Learning ×1
HQs:United States×8United Kingdom×1
Investments · 15 tracked
founders shown can be your intro pathBy year:2019 · 12018 · 12 dated
STRM.BIO develops a gene therapy delivery platform based on megakaryocyte-derived extracellular vesicles (STRM MVs) that target and deliver genetic cargoes preferentially to bone marrow and hematopoietic stem cells.
BiotechDeep TechMedical Devices
Co-investorsAscension VenturesBreakout LabsBreakout VenturesDelos CapitalKdT Ventures
Akadeum manufactures GMP-compliant ancillary materials for cell and gene therapy applications, specializing in microbubble-based negative selection products.
Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesAnn Arbor, US
Kalyan Handique(Executive Officer, Director)John Younger(Executive Officer, Director)James Militello(Executive Officer)
BoardJeffrey S. Williams(Director)Paul D'Amato(Director)Dan Kidle(Director)in
Co-investorsArboretum VenturesBeringeaBerkeley CatalystBlueStone Venture PartnerseLab VenturesID Ventures+5 more
Aronora is a clinical-stage biotech developing antithrombotic therapies, including factor XI/XIa inhibitors and thrombolytic drug candidates, to treat and manage thrombotic and thromboembolic conditions such as acute ischemic stroke, heart attack, and pulmonary embolism.
BiotechDeep TechHealthtechPortland, US
Erik I. Tucker(President & Chief Executive Officer)in
AvenCell develops next-generation CAR-T cell immunotherapies for hard-to-treat cancers, using proprietary Universal Switchable CAR and allogeneic platforms with an on/off mechanism combining universal effector cells and soluble Targeting Modules.
BiotechMedical Devices
Co-investorsEight Roads VenturesF-Prime Capital PartnersNovo Holdings
Cellular Origins provides automated cell therapy manufacturing solutions through its Constellation platform, which integrates robotics and digital management to enable GMP-compliant scaling of cell therapies with minimal process modification.
Advanced ManufacturingBiotechRoboticsCambridge, GB
Co-investorsHighland EuropeTTP Ventures
New York Blood Center provides blood products and clinical services, operates a genomics and cell solutions laboratory, runs a specialty pharmacy serving hemophilia treatment centers, and conducts biomedical research.
BiotechHealthtechMedical DevicesNew York, US
Functional Fluidics is a CLIA-certified diagnostic lab offering proprietary red blood cell function biomarker assays, starting with Sickle Cell Disease.
BiotechDigital HealthHealthtechMedical DevicesDetroit, US
Patrick Hines(CEO & Founder)Dr. Hines(Founder)John Cunningham(Chief Operating Officer)
Co-investorsID VenturesMichigan RiseSeae VenturesWavemaker Three-Sixty Health
HealthQuest Capital is a healthcare investment firm that funds and supports companies across medtech, digital health, and life sciences.
Digital HealthHealthtechMedical Devices
Co-investorsUnion Grove Venture Partners
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.
BiotechDeep TechHealthtechSeattle, US
Matthew Scholz(Founder)Sean Ainsworth(Chief Executive Officer)Robert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)Scott McIvor(Chief Development Officer)Richard Chin, M.D.(Director)
Co-investorsBioRock VenturesBoston Harbor AngelsBreakout VenturesEQx FundInvariantes FundMichigan Capital Network+1 more
KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply.
BiotechDeep TechHealthtechMedical DevicesBaltimore, US
Allan Doctor(Co-Founder & CSO)inDipanjan Pan(Co-Founder, Chief Technical Officer)inPhilip Spinella(Co-Founder, Chief Medical Officer)inDaniel Getman(Director)Gregory Lanza(Director)
Co-investorsBioAdvanceBioGenerator VenturesMaryland TEDCOOld Line Capital PartnersTEDCO
Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease.
AI & Machine LearningBiotechLongevityCambridge, US
Stan Wang(MD, PhD)inBing Lim(MD, PhD)inManish Jain
Co-investorsPillar VC
Vitestro develops Aletta®, an autonomous blood collection (phlebotomy) device that uses automation and clinical validation to standardize blood draws.
HealthtechMedical DevicesRobotics
Co-investorsSonder Capital
Portfolio news
latest coverage across their companiesImmusoft · immusoft.com · Mar 30, 2026
Akadeum Life Sciences · finsmes.com · Jun 4, 2025
Frequently asked questions
- How many investments has NYBC Ventures made?
- NYBC Ventures has 14 tracked investments.
- What stage does NYBC Ventures invest at?
- NYBC Ventures invests at the Seed, Series A, Series B stages.
- What sectors does NYBC Ventures focus on?
- NYBC Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is NYBC Ventures located?
- NYBC Ventures is headquartered in New York, US.
- Does NYBC Ventures lead rounds?
- NYBC Ventures typically participates in rounds rather than leading them.
- Who does NYBC Ventures co-invest with?
- NYBC Ventures most often shares deals with Breakout Ventures, ID Ventures, Michigan Capital Network, among 50 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.